Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Today's Featured Company
Tribute Pharmaceuticals Canada Inc. : (TBUFF:OTCQB) Tribute Pharmaceuticals Canada Inc. is a specialty pharmaceutical company that acquires, licenses, develops and sells healthcare products primarily in Canada, with additional global sales through its international partners for its proprietary products. Backed by a management team with deep industry experience and a track record of ramping sales into the hundreds of millions at prior companies, Tribute pursues a high-growth, low-risk strategy of in-licensing, or acquiring products that have already been through costly R&D and received regulatory approvals in other countries. More >
Streetwise Expert Interviews
To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst. In this, the last of his three interviews with The Life Sciences Report, Selvaraju highlights micro-, small- and mid-cap biotech names with therapies that may add years to patients' lives and liftoff to investor portfolios. (4/22/14) More >
To find undiscovered stories, investors must venture into unfamiliar territory. In this interview with The Life Sciences Report, we go halfway around the world to speak with Scott Power of Morgans Financial Ltd. about companies under coverage in Australia. Power helps investors get comfortable with the idea of putting money into newfound names, and unveils four strong ideas that could invigorate adventuresome portfolios and investors hungering for excitement. (4/17/14) More >
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular company has the potential to succeed in the fast-moving life sciences industry. In this interview with The Life Sciences Report, Zeng dissects his process and names 10 companies that have survived his exacting examination. (4/17/14) More >
including Don't Miss the Boat on Big Biotech Catalysts: Keith Markey (4/10/14) More >
including Hang On, Folks—It's Going to Be a Bumpy Ride: 2014 Biotech Watchlist Update (4/10/14) More >
"The American Heart Journal reported that CYTX's trial showed the procedure was safe, feasible and showed indications of a favorable benefit-to-risk profile." (4/14/14) Cytori Therapeutics Inc. - Henry McCusker, Scimitar Equity LLC More >
Learn More About Companies in This Issue
|Alliance for Regenerative Medicine|
BioLife Solutions Inc.
Cesca Therapeutics Inc.
|Cytori Therapeutics Inc.|
|Pluristem Therapeutics Inc.|
Life Sciences Tools & Diagnostics
|Amarantus BioScience Holdings Inc.|
BioLife Solutions Inc.
Cancer Genetics Inc.
OPKO Health Inc.
Verisante Technology Inc.